Researchers develop first inhibitors against key epigenetic complex involved in cancer

Activity of the polycomb repressive complex 1 is essential for the development and maintenance of leukemic cells; disrupting it presents a new potential therapeutic approach.

11:34 AM

Author | Ian Demsky

lime green structure with purple in left middle and lab note badge in navy and yellow in bottom right
Structure showing a PRC1 inhibitor developed at U-M in complex with the PRC1 RING domain.

Leukemia stem cells are rare cells that can renew themselves while continuing to generate malignant cells known as leukemic blasts. These cells are difficult to eradicate using chemotherapy drugs and frequently lead to recurrence of leukemia.

Leukemia stem cells, however, are dependent on a protein complex called polycomb repressive complex 1, or PRC1, which interacts with chromatin and turns genes off.

Now a team of researchers led by Tomasz Cierpicki, Ph.D., and Jolanta Grembecka, Ph.D., from the University of Michigan has developed the first small-molecule inhibitors of PRC1 — a first step toward developing a potential new therapeutic approach to treating acute myeloid leukemia by shutting down the activity of leukemia stem cells.

These inhibitors demonstrate activity in leukemia cells and patient samples, as reported in Nature Chemical Biology, and also open new opportunities to study the development of leukemia at the molecular level.

"Our lead compound, RB-3, represents an attractive and unique agent for studying PRC1 biology," said Cierpicki, an associate professor of biophysics and pathology at U-M. "This work demonstrates that directly targeting the activity of PRC1 is indeed feasible and could lay the groundwork for the development of new pharmaceutical agents for leukemia and possibly other cancers."

The study was a close collaboration between his lab and the lab of co-senior author Grembecka, an associate professor of pathology at Michigan Medicine and co-director of the developmental therapeutics program at the U-M Rogel Cancer Center.

Disclosure: The University of Michigan has applied for patent protection on the PRC1 inhibitors and several of the authors are listed as co-inventors.

Paper cited: "Small molecule inhibitors targeting Polycomb repressive complex 1 RING domain," Nature Chemical Biology. DOI: 10.1038/s41589-021-00815-5


More Articles About:

Lab Notes Leukemia Basic Science and Laboratory Research Cancer Research Cancer: Cancer Types
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

protein in pink and blue an light grey with lab note badge spelled out on bottom right in yellow background and navy font
Health Lab

Researchers Develop First-in-Class Inhibitors Against Key Leukemia Protein

Approach opens a new avenue to study the biology of acute leukemia and for the development new drugs.
MRNA splicing transcription on a blue background
Health Lab

Study reveals why a rare mutation behind Dravet syndrome is so deadly

Rare mutation behind Dravet syndrome found to be deadly.
Blue round cells in three pictures showing how they change under stress.
Health Lab

Timing is of the essence for RNA during stress

Key determiners of which RNA can be read to make proteins is time. Previous thinking was that a cell under threat would quickly make these RNAs in the nucleus and immediately push them into the cytoplasm.
Blue and yellow illustration of DNA helix
Health Lab

New anti-cancer strategy shows promise in preclinical studies

New cancer therapeutic strategy rewires protein interactions to improve efficacy and reduce potential side effects.
1906 psychopathic hospital
News Release

Exploring the mind’s mysteries: 130 years of mental health care & innovation at U-M

When it opened in 1906 on Catherine Street near the University of Michigan’s main hospitals, the stately brick State Psychopathic Hospital meant something new in the world of mental health.
Perforin increases endosomal-mitochondrial contact sites in tumor cells. Left is without perforin; right has perforin.
Health Lab

Immune system protein is a cancer killer on its own, new study shows

New study finds perforin can kill cancer tumor cells even when major granzymes were missing.